dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Mennini, Francesco S. |
dc.contributor.author | Marcellusi, Andrea |
dc.contributor.author | Robbins Scott, Sarah |
dc.contributor.author | Montilla, Simona |
dc.contributor.author | Craxi, Antonio |
dc.contributor.author | Buti Ferret, Maria |
dc.date.accessioned | 2021-06-29T10:43:08Z |
dc.date.available | 2021-06-29T10:43:08Z |
dc.date.issued | 2021-05 |
dc.identifier.citation | Mennini FS, Marcellusi A, Robbins Scott S, Montilla S, Craxi A, Buti M, et al. The Impact of Direct Acting Antivirals on Hepatitis C Virus Disease Burden and Associated Costs in Four European Countries. Liver Int. 2021 May;41(5):934-948. |
dc.identifier.issn | 1478-3231 |
dc.identifier.uri | https://hdl.handle.net/11351/6099 |
dc.description | Eliminació del VHC; Punt d'equilibri; Infecció d'hepatitis C |
dc.description.sponsorship | This study was partially supported by the Italian Ministry of Health Grant Number RF-2016-02364053 and by a Research Grant from the University of Tor Vergata Rome. The funding source had no role in the study design, the collection, analysis and interpretation of the data, in the writing of the report and in the decision to submit the paper for publication. |
dc.language.iso | eng |
dc.publisher | Wiley |
dc.relation.ispartofseries | Liver International;41(5) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Virus de l'hepatitis C |
dc.subject | Medicaments antivírics- Ús terapèutic |
dc.subject | Estalvi i inversió |
dc.subject.mesh | Hepatitis C |
dc.subject.mesh | Antiviral Agents |
dc.subject.mesh | /therapeutic use |
dc.subject.mesh | Cost Savings |
dc.title | The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1111/liv.14808 |
dc.subject.decs | hepatitis C |
dc.subject.decs | antivíricos |
dc.subject.decs | /uso terapéutico |
dc.subject.decs | ahorro de costes |
dc.relation.publishversion | https://onlinelibrary.wiley.com/doi/10.1111/liv.14808 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Mennini FS, Marcellusi A] Economic Evaluation and HTA, Centre for Economic and International Studies, (EEHTA-CEIS) Faculty of Economics, University of Rome “Tor Vergata”, Rome, Italy. Institute of Leadership and Management in Health, Kingston Business School, Kingston Univeristy, London, UK. [Robbins Scott S] Economic Evaluation and HTA, Centre for Economic and International Studies, (EEHTA-CEIS) Faculty of Economics, University of Rome “Tor Vergata”, Rome, Italy. [Montilla S] Department of Economic Strategy of Pharmaceutical Products, Italian Medicines Agency, Rome, Italy. [Craxi A] Gastroenterology and Hepatology Unit, Department of Internal Medicine and Medical Specialties "PROMISE", University of Palermo, Palermo, Italy. [Buti M] Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBER-EHD del Insitituto Carlos III, Barcelona, Spain |
dc.identifier.pmid | 33529499 |
dc.identifier.wos | 000621122300001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |